Mining and analysis of adverse drug event signals related to mepolizumab
- VernacularTitle:美泊利单抗相关不良事件信号的挖掘与分析
- Author:
Yaoxin CHEN
1
;
Shaoxing WU
2
;
Haoxuan LI
1
;
Yinji XU
2
Author Information
1. The Second Clinical Medical College，Guangzhou University of Chinese Medicine，Guangzhou 510405，China
2. Dept. of Respiratory and Critical Care Medicine，Guangdong Provincial Hospital of Traditional Chinese Medicine，Guangzhou 510120，China
- Publication Type:Journal Article
- Keywords:
mepolizumab;
adverse drug events;
signal mining;
rational drug use;
adverse drug reaction
- From:
China Pharmacy
2023;34(11):1374-1378
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide reference for rational clinical use of mepolizumab. METHODS The reporting odds ratio method and Bayesian confidence propagation neural network method were used to conduct signal mining and analysis of adverse drug event （ADE） reports related to mepolizumab in the United States Food and Drug Administration Adverse Event Reporting System from the first quarter of 2016 to the third quarter of 2022. RESULTS A total of 57 501 ADE reports were extracted with mepolizumab as the primary suspect drug， involving 16 358 patients. Among these reports， the proportion of males （23.51%） was lower than females （50.48%）. The reporting countries were primarily the United States （51.91%） and Canada （29.94%）. Consumers （71.18%） constituted the main reporting population. A total of 172 ADE-positive signals were identified， mainly involving 13 system organ classes such as the respiratory， thoracic and mediastinal disorders （41.63%）， as well as infectious and parasitic diseases （14.16%）. There were 60 high-risk signals， including 15 that were explicitly mentioned or related to adverse reactions in the drug instructions of mepolizumab and 45 signals （such as asthmatic crisis， sputum discoloured， purulent sputum， sleep disorder due to a general medical condition） were newly identified high-risk signals. Among them， 11 high-risk signals exhibited gender or age differences. CONCLUSIONS When clinically using mepolizumab， in addition to the adverse reactions mentioned in the drug instruction， special attention should also be given to changes in the nature of sputum， painful respiration， and sleep disorders.
